Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2009
01/28/2009CN101352425A Compound osmotic pump controlled release preparation and preparation method thereof
01/28/2009CN101352424A Cefdinir dispersible tablet and preparation method thereof
01/28/2009CN101352423A Omeprazole sodium lyophilized preparation for injection and preparation method thereof
01/28/2009CN101352422A Tetrodotoxin lyophilized powder formulation for injection and preparation method thereof
01/28/2009CN101352421A Method for preparing basically non-crystalline type telmisartan
01/28/2009CN101352420A Hydroxycamptothecin sustained-release microsphere and preparation method thereof
01/28/2009CN101352419A Acebrophylline sugar-free type granular formulation and preparation method thereof
01/28/2009CN101352418A Pirarubicin or pirarubicin hydrochloride lipid nano granule and preparation method thereof
01/28/2009CN101352417A Ambroxol hydrochloride oral solution and preparation method thereof
01/28/2009CN101352416A Luteolin solution composition
01/28/2009CN101352415A Dosage form and preparation method of acebrophylline oral solution
01/28/2009CN101352414A Compound anticancer sustained-release injection containing vascular inhibitor
01/28/2009CN101352413A Compound anticancer sustained-release injection containing clofarabine
01/28/2009CN101352411A Nimodipine solid dispersed formulation and preparation method thereof
01/28/2009CN101352409A Diclofenac sodium in situ forming eye gel
01/28/2009CN101352408A Alficetin in situ forming eye gel
01/28/2009CN100455962C Process for increasing liquid extraction from fabrics
01/28/2009CN100455618C Polyether glucoside ester large molecule compound and its preparation method
01/28/2009CN100455586C Pyrimidothiophene compounds
01/28/2009CN100455585C 7-polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups
01/28/2009CN100455582C Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
01/28/2009CN100455581C Imidazopyridine derivatives as melanocortin receptor agonists.
01/28/2009CN100455580C Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
01/28/2009CN100455579C Compounds and compositions as protein kinase inhibitors
01/28/2009CN100455578C Process for producing 2-acylthiophene compound
01/28/2009CN100455577C Novel substituted 1,2,4-trioxanes useful as antimalarial agents and a process for the preparation thereof
01/28/2009CN100455575C Isoselenothiazolidone compound and its complex and use thereof
01/28/2009CN100455574C Thiazoline acid derivatives
01/28/2009CN100455572C Dibenzo(b,f)azepine derivatives
01/28/2009CN100455571C Kukoline salt compounds and its preparation method
01/28/2009CN100455570C Quinolinone / benzoxazinone derivatives and uses thereof
01/28/2009CN100455568C 6-position substituted indoline, production and use thereof as medicament
01/28/2009CN100455567C Metal salt in iron group of dithiocarbamic acid for fishing medicine
01/28/2009CN100455566C Novel derivatives of aminocyclohexane
01/28/2009CN100455564C Histone de-acetylase inhibitor, preparation and application of pharmaceutical preparations of the same
01/28/2009CN100455560C Medicine precursor containing long chain fatty acyl group substituted venlafaxine and its prepn and use
01/28/2009CN100455314C Medication for treating cough
01/28/2009CN100455305C Externally applied powder
01/28/2009CN100455292C Anti-fatigue formulating prescription
01/28/2009CN100455291C Notoginseng medicine composition for treating cardiac and cerebral vascular diseases
01/28/2009CN100455290C Novel receptors for dollar i(helicobacter pylori) and use thereof
01/28/2009CN100455289C Anticancer compositions comprising methenamine
01/28/2009CN100455288C Formula of Reynoldazine hydrochloride prepn.
01/28/2009CN100455287C Formulations
01/28/2009CN100455286C Injection of palonosetron and preparation process thereof
01/28/2009CN100455285C Albendazole new form for treating adenoid hypertrophy
01/28/2009CN100455284C Compound with P-glycoprotein inhibiting and multidrug-resisting reversing function and its salt
01/28/2009CN100455283C Medicine containing acarnine compound as active component
01/28/2009CN100455282C Process for producing medicine
01/28/2009CN100455279C Oral administered sustained release lozenge composition and its preparation method
01/28/2009CN100455275C Medical device with coating that promotes endothelial cell adherence and differentiation
01/28/2009CN100455216C OPC beverage and its making method
01/28/2009CN100455195C Synergistic microbicidal combination
01/27/2009US7482504 Dressing for treatment of short wounds located in high tension areas
01/27/2009US7482491 Amino alcohol derivative, addition salt thereof, and immunosuppressant
01/27/2009US7482489 Enantiomerically pure (R)-albuterol dibenzoyltartrate and protected analogs thereof
01/27/2009US7482488 (E)-N-(4-methoxy-3-nitrophenyl)-3-(3,4,5-trimethoxyphenyl)-2-propenamide; as antiproliferative agents, radioprotective agents and cytoprotective agents, anticancer agents
01/27/2009US7482487 Phenylaminoethanol derivatives as β2 receptor agonists
01/27/2009US7482483 calixarenes having acyclic isophthalic acid groups attached, used as target for platelet derived growth factors or vascular endothelial growth factors; angiogenesis inhibitors, antiproliferative, antitumor or anticarcinogenic agents
01/27/2009US7482475 5-((((2R)-1-(4-((S)-1-hydroxyhexyl)phenyl)-4-methyl-5-oxopyrrolidin-2-yl)methoxy)methyl)thiophene-2-carboxylic acid; glaucoma or ocular hypertension
01/27/2009US7482472 Such as 2-(4-[[(5-chloro-2-thienyl)carbonyl]amino]-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)acetic acid; blood coagulation; treating thromboembolic disorders (myocardial infarction, angina pectoris, reocclusions and restenoses after angioplasty/aortocoronary bypass, stroke), atherosclerosis and arthritis
01/27/2009US7482470 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
01/27/2009US7482469 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives
01/27/2009US7482466 Hydroxamates as therapeutic agents
01/27/2009US7482465 Indol derivatives and their use as 5-HT ligands
01/27/2009US7482462 Immunosuppressants for treating skin disorders, acne, alopecia, estrogen- or androgen-dependent tumors, rheumatoid arthritis, type I and II diabetes, lupus erythematosus, multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis, contact dermatitis, graft versus host disease, eczema, asthma
01/27/2009US7482461 3-(1-methylpiperidin-4-yl)-5-(1-naphthylsulfonyl)-1H-indazole, central nervous system disorder
01/27/2009US7482460 Doxepin analogs and methods of use thereof
01/27/2009US7482458 Quinoline derivatives
01/27/2009US7482455 Chemical compounds
01/27/2009US7482454 Antimicrobial quinolones, their compositions, and uses
01/27/2009US7482448 Compounds and compositions as cathepsin inhibitors
01/27/2009US7482439 Caprazene as novel compound and derivatives thereof, and caprazol as novel compound and derivatives thereof
01/27/2009US7482428 Optimized expression of HPV 31 L1 in yeast
01/27/2009US7482383 Emulsion containing a plant extract, method for producing said emulsion and for obtaining said plant extract
01/27/2009US7482380 Cyclopropanated macrocyclic ketones and lactones
01/27/2009US7482379 protease inhibitors more specifically to peptide inhibitors of cysteine proteases; viral infections, stroke, neurodegenerative disease, inflammatory diseases,autoimmune diseases like lupus, cancer; alpha aza-amino acid residues; prevent proteolysis
01/27/2009US7482378 Physiological cooling compositions
01/27/2009US7482377 Administering an immediate release oral dosage of diclofenac or in salt form together with one or more alkali metal bicarbonates in an amount of >20% by weight; palatable and free from any unpleasant taste or side effects; short time to the maximum plasma concentration; high maximum plasma concentration
01/27/2009US7482376 Conjugated complement cascade inhibitors
01/27/2009US7482375 Compounds useful in therapy
01/27/2009US7482374 Pyrrolidine-2-ones as Factor Xa inhibitors
01/27/2009US7482373 useful in the treatment of central or peripheral nervous system disorders; psychological disorders; gastrointestinal disorders
01/27/2009US7482372 Antiinflammatory; cartilage protecting therapeutics; antiarthritic agent; N-{4-[(2-methyl-4-quinolinyl)methoxy]phenyl}-2,4-dioxo-1,3-diazaspiro[4.5]decane-6-carboxamide; 2-(2,5-dioxo-4-imidazolidinyl)-N-{4-[(2-methyl-4-quinolinyl)methoxy]phenyl)acetamide
01/27/2009US7482370 Compounds for the treatment of inflammatory disorders
01/27/2009US7482369 Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors
01/27/2009US7482368 Triamide-substituted heterobicyclic compounds
01/27/2009US7482367 Substituted benzimidazoles and methods of their use
01/27/2009US7482366 Modulators of LXR
01/27/2009US7482365 Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
01/27/2009US7482364 Histamine H3 antagonists; do not contain imidazolyl moiety; such as 1-[4-(4-piperidin-1-ylmethyl-phenyl)-but-3-ynyl]-piperidine
01/27/2009US7482363 N-[[4-(2-Chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl benzenesulfonamide, used for prophylaxis of respiratory system disorders or as antiallergens
01/27/2009US7482362 Substituted-4-quinolones
01/27/2009US7482361 Crystalline form for quinapril hydrochloride and process for preparing the same
01/27/2009US7482360 Fused tetracyclic mGluR1 antagonists as therapeutic agents
01/27/2009US7482359 Androgen receptor modulators
01/27/2009US7482358 2-(5-cyano-3-pyridyl)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridyl)-5-methyl-2-imidazoline; obesity, bulimia; antidiabetic agents; neuropeptide Y receptor antagonists
01/27/2009US7482357 N-(pyridin-2-ylmethyl)-4-methyl-3-oxo-4-aza-5 alpha -androst-1-en-17 beta -acetamide; enhancement of weakened muscle tone; osteoporosis, bone disorders; ; periodontal disease, frailty, aging skin, male hypogonadism, postmenopausal symptoms, inflammatory arthritis, cachexia, Alzheimer's disease
01/27/2009US7482356 Bicyclic pyrazolone cytokine inhibitors
01/27/2009US7482355 Pyrimidine derivatives as modulators of chemokine receptor activity